At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 65 enrolled
Drug / intervention
Ketamine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Biomarker Assessment of Glutamatergic Target Engagement
In Brief
A Phase 4 clinical trial evaluating Ketamine and Normal saline for Healthy Controls. Completed, enrolled 65 participants across 3 sites.
Detailed Summary
The purpose of this study is to assess the relative feasibility of 2 potential functional measures of target engagement (Glx MRS, BOLD fMRI) to systematically assess mGluR 2/3 in drug development for psychotic spectrum disorders.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Controls
CountriesUnited States
CollaboratorsNational Institute of Mental Health (NIMH)
Timeline
Phase 4CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartMay 2014
First PostedMay 2014
Primary CompletionOct 2015
Study CompletionNov 2015
TodayJul 2026
First PostedMay 9, 2014
Enrollment StartMay 1, 2014
Primary CompletionOct 1, 2015
Study CompletionNov 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 12.1 years ago
Interventions
Ketaminedrug
intravenous infusion of saline solution with ketamine
Normal salinedrug
Normal saline will be used for placebo in this group